Milestone Scientific 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 revenue was $2.2 million, compared with $2.4 million in the same period last year; management attributed the decline primarily to lower dental product sales, partially offset by medical sales growth and higher dental repair income.
- Medical segment revenue grew 136% year over year, while gross profit was $1.6 million, consistent with the prior-year period.
- Gross margin improved to 72.3% from 69.5%, operating expenses declined 15.3% to $2.4 million, and operating loss improved to $746,000 from $1.1 million.
- Net loss narrowed to $748,000, or $0.01 per share, from $1.2 million a year ago.
- As of September 30th, the company had $1.3 million in cash and cash equivalents, working capital of $3.5 million, and no outstanding debt after converting outstanding director loans to equity.
- Management identified approximately $400,000 in additional annual savings and reduced expenses under an existing agreement to approximately $91,000 for the first 9 months of 2026 from $350,001 in the prior-year period.
- The company reported clinical use of CompiFlow at Rothman Orthopaedics, added pain and spine specialists spanning 22 locations across 4 states to its advisor program, and said it has more than 500 US commercial leads supported by 5 dedicated medical sales professionals, approximately 15 sales consultants, 3 distribution partners, and RedOne Medical.
- Online dental product demonstrations more than doubled compared with the same period last year, and the company is discussing distribution with 4 major dental distribution channels.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, everyone, and welcome to Milestone Scientific Inc. Q3 2026 Financial Results and Business Update Conference Call. At this time, all participants are placed on a listen-only mode. If you have any questions or comments during the presentation, you may press star one on your phone to enter the question queue at any time, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to hand the floor over to your host, James Carbonara with Hayden IR. Sir, the floor is yours.
Thank you, operator. Before we begin, please note that today's call will contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Please refer to our earnings press release, as well as our filings with the SEC, including our 2025 Form 10-K, for a discussion of these risks. A replay of this call will be available shortly after its conclusion. With that, I'll turn the call over to our CEO, Eric Hines.
Thank you, James, and good morning, everybody, and thank you for joining our call today. Our third quarter results reflect continued execution of our commercial strategy and disciplined cost management. Total revenue was $2.2 million as expected, a modest sequential decline following the two large international orders that benefited our second quarter. Medical segment revenue grew 136% year-over-year. Gross margin improved 280 basis points to 72.3%, and operating expenses declined 15.3%. Net loss narrowed to $748,000 from $1.2 million a year ago. Just as importantly, our team identified approximately $400,000 in additional annual savings, which we believe supports our expectation to approach or achieve profitability in the fourth quarter of 2026. I'm just going to reiterate that one more time. Our expectation to approach or achieve profitability in the fourth quarter of 2026.
In our medical business, our priority is converting growing interest in CompuFlo into sustained clinical adoption and recurring disposable revenue. We are gaining traction with major healthcare organizations, highlighted by the initiation of clinical use at Rothman Orthopaedics, a nationally recognized orthopedic institution with 34 locations. During the quarter, we also added Pain and Spine Specialists, spanning 22 locations across four states, and its Medical Director, Dr. Sudhir Rao, to our CompuFlo Advisor Program. To support that adoption, we are expanding our commercial infrastructure. We now have more than 500 U.S. commercial leads, supported by five dedicated medical sales professionals, approximately 15 sales consultants, and three distribution partners, and Red One Medical, who provides access to federal healthcare customers, including the VA and the Department of Defense. The medical business opportunity is significant.
There are an estimated 30 million-plus epidural procedures annually worldwide, including more than 11 million in the U.S. For illustrative purposes, just 2% penetration of the U.S. market at an assumed selling price of $150 per procedure would represent approximately $33 million in potential annual disposable revenue. That is not a revenue projection, but it shows the size of the market. Beyond epidurals, we recently submitted a provisional patent application for a new use of CompuFlo in intrathecal pump refills, and internationally, we are pursuing go-to-market and licensing initiatives with a few large medical technology organizations. Our dental business remains an important foundation for growth. Online product demonstrations more than doubled compared with the same period last year, reflecting stronger customer engagement.
We are also accelerating our market expansion strategy through discussions with four major dental distribution channels that collectively serve thousands, if not tens of thousands, of dental offices, positioning us to reach previously untapped markets and drive broader adoption. We also strengthened our balance sheet by converting our outstanding director loans to equity, leaving us debt-free as of September 30th. In addition, we evaluated and optimized our contractual obligations under an existing agreement, which lowered the related expense to approximately $91,000 for the first nine months of 2026 from $351,000 in the prior year period, and it is a source of additional annual savings I mentioned at the start of the call. Looking ahead, we are reaffirming our 2026 outlook of a range of $9.8 million-$10.2 million, representing double-digit growth, and we continue to expect significant growth in CompuFlo sales. We believe we are approaching an important inflection point.
Based on our current visibility, we expect to approach profitability or be profitable in the fourth quarter of 2026. For 2027, we expect considerably lower costs than this year, and we expect to deliver additional profitable quarters, although results may vary from quarter to quarter depending on revenue levels. With our lower expense base, we believe quarterly revenue of approximately $2.6 million-$2.7 million puts us near the threshold where incremental revenue begins to flow meaningfully to the bottom line. That operating leverage, combined with growing medical adoption and recurring disposable revenue, creates what we believe is a path to sustained profitability and long-term value for our shareholders. With that, I am going to turn the call over to Keisha to review our third quarter financial results.
Keisha? Thank you, Eric, and good morning, everyone.
Total revenue for the third quarter was $2.2 million compared to $2.4 million in the same period last year, a decrease of $140,000 or 5.9%. The year-over-year decline was primarily driven by lower dental product sales, partially offset by the growth in the medical sales and higher dental repair income. Gross profit was $1.6 million, consistent with the prior year period. Gross margin improved to 72.3% compared to 69.5% for last year, primarily reflecting lower product costs. Operating expense decreased by 15.3% to $2.4 million compared to $2.8 million in the third quarter of 2025. This reduction was primarily driven by lower salary, compensation, stock-based compensation, professional fees, contract-related expenses, partially offset by higher marketing, regulatory, warehousing, and travel expense. Operating loss was $746,000, an improvement compared to the operating losses of $1.1 million for the prior year.
This improvement was driven by a robust gross margin and our ongoing efforts to managing operating expense. Net loss for the quarter was $748,000, minus $0.01 per share compared to the net loss of $1.2 million. Turning to our balance sheet, as of September 30th, we had $1.3 million in cash and cash equivalents, working capital of $3.5 million, and no outstanding debt. With that, I'll turn it back over to the operator for questions.
Certainly. Everyone, at this time, conducting a question-and-answer session. If you have any questions or comments, please press star one on your phone at this time. We do ask that while posing a question, please pick up your handset if you're listening on speakerphone to provide optimum sound quality. And once again, if you have any questions or comments, please press star one on your phone. Your first question is coming from Bruce Jackson from StoneX. Your line is live. Hi, good morning.
Just wanted to start with the gross margins that ticked up nicely here sequentially. Is this something that is sustainable going forward, and how should we be thinking about that particular line item?
Hey, Bruce. Thanks for your question. We actually talked with Keisha about that this morning. I would expect that we will fall back into the 70% range. It's a blended rate, of course, between the equipment and the disposables. We have some quarters where we have larger equipment sales, specifically when we're selling into China, large orders into China. So, I would expect that the proper representation of the gross margin is in the 69%-70% range moving forward, although there might be some occasional fluctuations to the positive there.
Okay. Are there any seasonal trends in your business? I mean, you've got a lot of potential contracts lined up here, and fourth quarter can generally be strong for capital equipment sales. Is that what you're seeing right now this year?
Yeah, there's a little bit of seasonality just from the dental business. There's a lot of people that are, especially in Europe and so forth, on vacations in the summertime frame. For the fourth quarter, generally, it's a strong quarter, as you mentioned. Q1's generally strong. Q2 can slow down a little bit in Q3, but for the most part, Q4 is a strong quarter.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
